VivoSeq
Other

LDL-Cholesterol

0

Pipeline Programs↗

0

Active Trials↗

5

Companies Involved↗

LDL-cholesterol is an early-stage landscape with 0 programs across 5 companies. The most active players are Otsuka, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

87/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Otsuka logo

Otsuka

0 programs

PreclinicalP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalC

Civi Biopharma, Inc.

0 programs

PreclinicalK

Kastle Therapeutics, LLC

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

17

clinical trials

Completed13 · 76%
Terminated2 · 12%
Unknown status2 · 12%

Clinical Trials

Trial Activity

17 trials

Evaluation of a Probiotic on LDL-cholesterol Levels
Completed·BBiosearch S.A.·Phase 1·NCT04029818·40 enrolled
A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00136942·370 enrolled
Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol
Completed·Sanofi logoSanofi·Phase 1·NCT01959971·20 enrolled
A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level
Completed·CCivi Biopharma, Inc.·Phase 1·NCT03427710·36 enrolled
Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels
Completed·KKastle Therapeutics, LLC·Phase 2·NCT00216463·50 enrolled
A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
Completed·Otsuka logoOtsuka·Phase 3·NCT05683340·96 enrolled
A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
Completed·Otsuka logoOtsuka·Phase 3·NCT05687071·130 enrolled
Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)
Completed·—·N/A·NCT00762229·39 enrolled
Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI
Completed·PPopulation Health Research Institute·Phase 2·NCT03718286·97 enrolled
LDL-Cholesterol Lowering Effect of KB2115 as Add on to Statin
Completed·KKaro Bio AB·Phase 2·NCT00593047·180 enrolled
Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis
Completed·LLudwig-Maximilians - University of Munich·Phase 3·NCT01598948·17 enrolled
Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCI
Completed·SSamsung Medical Center·N/A·NCT06338956·135,877 enrolled
LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe
Completed·KKaro Bio AB·Phase 2·NCT00677248·120 enrolled
Pharmacodynamic Clinical Trial of Cardiovascular Polypill on LDL Cholesterol
Terminated·—·Phase 2·NCT01362218·107 enrolled
Impact of LDL-cholesterol Lowering on Platelet Activation
Terminated·—·Phase 4·NCT03331666·4 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)